[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bioprojet\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100598631","phase-2-proof-of-concept-study-on-bp14979-effect-on-essential-tremor-100598631",false,"NCT07074002","Proof of Concept Study on BP1.4979 Effect on Essential Tremor","A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of BP1.4979 in Adult Patients With Essential Tremor","Inclusion Criteria:\n\n* Male or female ≥18-85 years old\n* Confirmed diagnosis of ET, characterized by meeting the following criteria: (a) the presence of a bilateral upper limb action tremor that occurs in isolation; (b) a minimum duration of 3 years; and (c) the tremor may or may not be present in other areas such as the voice, or lower limbs\n* ET characterized by a TETRAS-P score of at least 1.5 in either the forward posture, wing beating posture, or finger-to-nose movement of at least one upper extremity\n* Female patient: post-menopausal woman having at least 12 months of natural amenorrhea without any alternative medical cause, or woman of childbearing potential using a highly effective method of contraception for the duration of the trial and for 1 month after stopping the investigational medication\n\nExclusion Criteria:\n\n* Severe tremor, defined as patient with ET characterized by a TETRAS-P score of ≥ 3 in either the forward posture, wing beating posture, or finger-to-nose movement of at least one upper extremity, or tremor of trunk\n* Isolated head tremor not accompanied with tremor of any other body part\n* Medical history or clinical evidence of any other conditions, whether medical, neurological, or psychiatric, that could potentially explain or contribute to the presence of tremors\n* Patient who takes a medication which may induce tremor\n* Direct or indirect injury or trauma to the nervous system within 3 months before the onset of tremor\n* Concomitant treatment with more than three drugs to treat ET\n* Any prior procedures for the treatment of ET such as deep brain stimulation, brain lesioning, or magnetic resonance (MR)-guided procedures, including MR-guided focused ultrasound","ALL","18 Years","85 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if drug BP1.4979 works to treat essential tremors in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are:\n\n* Does the drug BP1.4979 reduce tremors in individuals with essential tremor?\n* Do participants have a good safety and tolerability of drug BP1.4979?\n\nResearchers will compare drug BP1.4979 to a placebo (a look-alike substance that contains no drug) to see if drug BP1.4979 works to treat essential tremors.\n\nParticipants will:\n\n* Take the study drug (active or a placebo) twice daily over a 4-week period\n* Visit the clinic 5 times for health checkups and questionnaires completion over a period of approximately 7 to 10 weeks\n* Complete a diary weekly to assess the impact of essential tremor on daily life",[27],"Essential Tremor",[27],"RECRUITING","2025-12-09",{"date":32,"type":33},"2025-12-16","ACTUAL",{"date":35,"type":33},"2025-09-17",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"Bioprojet","OTHER",14,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":68},"100596587","phase-2-proof-of-concept-study-on-bp14979-effect-on-primary-premature-ejaculation-100596587","NCT07047404","Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of BP1.4979 in Adult Patients With Primary Premature Ejaculation","Inclusion Criteria:\n\n* Males aged 18 to 50 years old (both inclusive)\n* Diagnosis of primary (lifelong) PE according to the investigator\n* Intravaginal Ejaculatory Latency Time (IELT) estimated by the patient around one (1) minute at screening\n* Confirmation at randomization visit that at least 3 timed sexual intercourses with each IELT below 90 seconds occurred during the baseline period\n* Patient must be able to provide an informed consent and voluntarily express a willingness to participate in this study, and must sign and date an informed consent prior to any study specific procedure\n* Capability to participate in all study tests according to the investigator\n\nExclusion Criteria:\n\n* Diagnosis of acquired PE, pseudo-PE or natural variable PE\n* History of clinically significant abnormalities comprising cardiovascular (including especially prolonged QTc (\\>450 ms) and high degree (second and third) atrio-ventricular blocks)), hematological, neurological, and endocrine diseases\n* Current therapy with any treatment which may impact PE from 4 weeks prior to the screening visit\n* Current therapy with any treatment displaying dopamine D3 receptor agonist properties from 4 weeks prior to the screening visit\n* Concomitant intake of psychoactive \u002F chem-sex substances","MALE","50 Years",{"count":52,"type":21},60,[24],"The goal of this clinical trial is to learn if drug BP1.4979 works to treat primary premature ejaculation in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are:\n\n* Does drug BP1.4979 increase the time to ejaculation during sexual intercourse?\n* Do participants have a good safety and tolerability of drug BP1.4979? Researchers will compare drug BP1.4979 to a placebo (a look-alike substance that contains no drug) to see if drug BP1.4979 works to treat primary premature ejaculation.\n\nParticipants will:\n\n* Take drug primary premature ejaculation or a placebo per requested need prior to sexual intercourses for 12 weeks\n* Visit the clinic 4 times for checkups and questionnaires completion and have 2 phone calls with the study team over a period of about 17 weeks\n* Keep a diary of the intakes of the experimental drug, ejaculation time, ejaculation control, any unusual events concerning their health and any other medication taken",[56],"Premature (Early) Ejaculation",[58,59,60],"premature (early) ejaculation","primary premature ejaculation","Lifelong premature ejaculation","2025-10-01",{"date":63,"type":33},"2025-10-06",{"date":65,"type":33},"2025-09-15",{"date":37,"type":21},{"name":39,"class":40},1,""]